Contrast Enhanced Mammography Imaging Screening Trial (CMIST)

The Contrast Enhanced Mammography Imaging Screening Trial (CMIST) is designed to compare contrast enhanced spectral mammography (CESM) performance in screening women with mammographically dense breasts (BI-RADS density categories c and d), ages 40-75, at average-to-intermediate risk for breast cancer, to that of the combination of digital breast tomosynthesis (DBT) and whole breast ultrasound (WBUS).

The CMIST study is expected to launch in the second quarter of 2020.

Study Background


  CMIST Trial
The CMIST Trial seeks to determine if contrast enhanced
spectral mammography (CESM) screening provides more
accurate cancer detection than current screening methods
in women with dense breasts.

With the increasing adoption of DBT and the proliferation of supplemental screening breast ultrasound due to state and federal breast density notifications laws, many women with dense breasts now undergo combined annual screening with both DBT and WBUS.

Although this approach leads to a modest improvement in cancer detection, experts have raised concerns that it is time consuming, has a high false positive rate and leads to unnecessary biopsies and increased healthcare costs.

CESM  combines mammography and vascular based screening methods that could offer a more efficient screening approach.

The planned trial will be managed by the American College of Radiology (ACR) Center for Research and Innovation with support from the Breast Cancer Research Foundation  and GE Healthcare.